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For nearly 40 years, the U.S. National Cancer Institute (NCI) has funded health-related
quality-of-life (HRQOL) and symptommanagement in oncology clinical trials as a method
for including a cancer patient’s experience during and after treatment. The NCI’s
planned scope for HRQOL, symptom and patient-reported outcomes management
research is explained as it pertains to radiopharmaceutical clinical development. An effort
already underway to support protocol authoring via an NCI Cancer Therapy Evaluation
Program (CTEP) Centralized Protocol Writing Service (CPWS) is described as this service
aids incorporation of HRQOL, symptom and patient-reported outcomes management
research into sponsored protocols.
Keywords: radiopharmaceutical, cancer, patient reported outcome (PRO), digital device usage, clinical outcome
assessment, radiotherapy, radiotherapy adverse effects
INTRODUCTION
For nearly four decades, the National Cancer Institute (NCI) sponsored clinical trials have provided
resources for research in health-related quality of life (HRQOL) and in symptom management for
cancer patients (1). These resources have included infrastructure for cancer patient clinical trials
that have symptoms as a primary end point, funding for investigator-initiated correlative studies
involving HRQOL end points in late phase clinical trials, and grants studying the key issues and
challenges facing investigators for implementing HRQOL and symptommanagement into its early
phase clinical trials (1, 2).
Late phase clinical trials seek to improve cancer patient survival and more consideration has
been given in these trials to the way in which cancer patients live during and after their treatments.
A desire to meet HRQOL needs of cancer patients has incentivized NCI sponsored clinical trials
to consider piloting the collection of HRQOL and patient-reported outcomes (PROs) by wearable
digital technology like mobile phone applications or wristband sensors in parallel with its early
phase clinical trials of radiopharmaceuticals. NCI sponsored clinical trials offer this strategic vision
because radiopharmaceuticals have drug-like pharmacology in that these radioactive drugs have
quantifiable pharmacokinetics, body weight-driven prescriptions, and predictable organ toxicities.
Radiopharmaceuticals fit well into the programmatic mission of patient safety and symptom
management for NCI sponsored clinical trials. Thus, integrating pilot HRQOL tools into early
phase safety trials that are eventually intended to be used in late phase efficacy trials makes sense (3).
Wearable digital technology in the form ofmobile phone applications or wristband sensors captures
in near-time the HRQOL and PRO data linked to acute toxicity, prompt and iterative symptom
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management, as well as reasons for treatment-related drug
holiday or drug discontinuation (4).
The challenges and opportunities for integrating PRO
and biometric endpoints into the roll-out of NCI sponsored
radiopharmaceutical trials are discussed as the primary emphasis
of this article. Opportunistic examples related to the Cancer
Therapy Evaluation Program (CTEP) Centralized Protocol
Writing Service (CPWS) and its incorporation of HRQOL,
symptom and patient-reported outcomes management research
into early-phase patient safety trials of radium-223 (Xofigo)
or lutetium-177 dotatate (Lutathera) provide context for
the discussion.
CHALLENGES AND OPPORTUNITIES
From the time of cancer diagnosis to the end of life, cancer
patients encounter a variety of functional and physical challenges
(1). Undesirable outcomes from cancer or its treatment may
range in scope from transient and reversible (for example,
nausea or low white blood cell count), to cumulative (fatigue
or abdominal pain), to subacute (3-month post-therapy cough
from pneumonitis), or to late persistent and unremitting (dry
mouth or vaginal dryness) (5). Pain, fatigue, and nausea are the
most commonly encountered symptoms that occur along the
trajectory of modern radiopharmaceutical treatment experience
(6, 7). Cancer patients given radiopharmaceuticals may also have
decreased appetite, vomiting, bruising easily, diarrhea, aching
joints or muscles, or headache at various stages of their illness
(6, 7). If not managed prospectively, a radiopharmaceutical-
treated patient’s physical, mental, or emotional well-being might
be disrupted, thus impacting routine activities of daily living
(Figure 1). Despite the long existence of these concepts (8), only
now are “wearable” opportunities for symptom data collection
becoming a reality (9). Wearable digital technology has evolved
biometrics, or a capacity to observe, detect, and quantify, or
in appropriate instances to intervene in, health parameters of
the human body. Digital devices like wristband sensors now
compute fitness and hydration level or out-of-bed activity and
duration (Figure 1).
For many patient-reported symptoms, meaningful
interventions have not been well-studied due to a scarcity
of data on the incidence, prevalence, trajectory, and severity
of symptoms (1). There is an imperfect knowledge of the
physiologic mechanisms underlying symptoms altered by cancer
treatments. NCI sponsored clinical trials offer a mechanism for
scientifically and intellectually interesting radiopharmaceutical
studies that incorporate HRQOL and PRO end points because
they provide an opportunity safely and efficiently to study
toxicity from the viewpoint of the patient in a near-time digital
format. Currently, a number of projects to address HRQOL and
PRO research gaps using digital technology are considered in
NCI sponsored clinical trials. Indeed, digital technology might
improve near real-time collection of HRQOL and PRO end
points (10), but might also impact patient outcomes (11). Digital
devices like a mobile phone application could capture near-time




From the outset, NCI sponsored clinical trials use an existing
five-point scale Common Terminology Criteria for Adverse
Events (CTCAE, version 5) toolbox for safety data and
adverse event evaluation on radiopharmaceutical trials. While
this method has limitations (Table 1), this approach builds
upon prior notions that radiopharmaceutical-attributed toxicity
falls into discrete toxicity categories that require medical
instruments, technical training, or observable or subjective
components (5, 12). For now, NCI investigators consider
adverse events detected by instruments or those providers
with technical training to follow CTCAE terminology and
grading of severity. Adverse events that are subjective in nature
with observable aspects (like radiation-induced diarrhea) or
without observable qualities (like radiation-induced nausea)
are amenable to patient reporting. Take for instance a trial
participant’s pretreatment grade 1 severity of frequent loose
stools. On a trial evaluating the radiopharmaceutical radium-223
[a calcium mimetic eliminated via the relatively radiosensitive
large intestine (13)], a participant’s post-treatment severity of
frequent loose stools might rise to grade 2, require antidiarrheal
medication, and interfere with grocery shopping. CTCAE
reports would capture the objective severity of loose stools
requiring a physician-directed intervention in this case, but
not necessarily the specific disruption of an instrumental
activity of daily living. A PRO-CTCAE (v1.0) toolbox (14)
incorporated into a radiopharmaceutical trial might improve
the evaluation of this adverse event and provide the patient
experience (Table 2). In this case scenario, capturing the
patient’s perspective on diarrheal frequency offers better qualified
information on how an individual participant lives during and
after their radiopharmaceutical treatment. For this reason, NCI
investigators plan to list select toxicities like diarrhea as an
adverse event of special interest when studying radium-223. As
iterated elsewhere, an adverse event of special interest is a toxicity
for which an expedited adverse event report must be filed to the
NCI in its sponsored trials (5). PRO-CTCAE data have not been
collected on radiopharmaceutical trials before, in part, because
collection of such data is not common in early phase trials.
Biometric data for trial endpoints (e.g., fasting glucose or specific
changes in systolic and diastolic blood pressure parameters) are
integrated in some NCI sponsored clinical trials.
Collection of biometric data or patient-reported outcomes
in radiopharmaceutical trials is recommended. Investigators
should consider employing the HRQOL instruments that
measure, as optimally as possible, the relevant toxicity domains
particularly relevant to the agent’s mechanism of action
(e.g., such as a radiopharmaceutical acting as a calcium
mimetic and causing diarrhea), residence time (i.e., how
long does a radiopharmaceutical “stick” to a target), and
elimination from the body (like bowel or renal excretion
inducing radiation-related enteritis or cystitis). A trial can
incorporate the PRO instrument to provide information on
specific symptoms or functional status, and any impact of
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FIGURE 1 | Development of digital patient-reported outcome measures for radiopharmaceuticals. Wearable digital technology is now commonplace among cancer
patients. Patient-reported outcomes (PRO) or common terminology criteria for adverse events (CTCAE) items can be digitized for capture in the clinical development
of radiopharmaceuticals. (A) Depicts an example of a bone-homing radiopharmaceutical intending to irradiate overlying cancer cells in the nearby bone marrow. It also
shows that the radiopharmaceutical can irradiate osteocytes in a bone’s mineralized matrix or bone marrow progenitor cells. Alpha particle-, beta particle-, or
conversion electron-emitting radiopharmaceuticals would all have differential effects on normal cells depending on the range of irradiation. (B) Indicates what
symptoms or clinical signs might manifest after multiple cycles of radiopharmaceutical administration. For example, PRO events like fatigue or CTCAE events like
anemia that lessen overall performance status could become apparent. (C) Depicts some available commercial devices that quantifiably track activity or hydration
status that might reflect some PRO or CTCAE items, or, digitally capture patient experiences in near real-time through applications or chatbots. Further research with
wearable digital technology is needed.
the cancer and its treatment on HRQOL. Studies indicate
that well-designed and well-conducted HRQOL research
might guide future clinical trial design and morbidity end
points by identifying certain patient conditions that variably
confound HRQOL (14–16). For the best return on research
investment, HRQOL research should detect HRQOL items
both important to patients and likely to be impacted by the
radiopharmaceutical intervention or the underlying cancer
(1). As more trials find effective treatments, both patients and
their physicians will want data on HRQOL and the influence
radiopharmaceuticals will have on their physical health and
functional performance.
Because of the ongoing discussions to incorporate
HRQOL and symptom management in its randomized trials,
NCI stakeholders have adapted CONSORT (consolidated
standards of reporting trials) guidelines (17) for the
reporting of radiopharmaceutical clinical trials that might
incorporate such end points (Table 3). To date, there are
no formal examples in which radiopharmaceutical trials
have included HRQOL instruments. NCI stakeholders share
their thoughts on this topic here as this sort of data in
its trials should provide, to future patients and to their
physicians, information regarding an expected course of
radiopharmaceutical therapy alone or in combination.
Such data should also define potential for recovery from
radiopharmaceutical-related toxicity.
Digital therapeutics provide another opportunity for
advancements (18). These interventions are often pushed
onward to the health consumer by high-quality software
programs that integrate protocol-defined management steps
to prevent, manage, or treat a medical disorder or a disease
like cancer (18). Independently or together with medications,
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TABLE 1 | Complementary use of CTCAE and patient-reported outcome item formats for radiopharmaceuticals*.
CTCAE version 5 items PRO-CTCAE version 1.0 items
Primary utility Report toxic effect of radiopharmaceutical Report health status of patient
Best uses Objective assessment (overt sign like hair loss) Subjective assessment (obscure symptom like fatigue)
Best captures Severity, for physician-directed intervention Interference, for quality of life and treatment compliance
Validity Not rigorously tested Tested, with guidance for implementation (8)
Reliability Not rigorously tested Tested
Methods of data capture Clinical interpretation, multilayered Direct report from patient given radiopharmaceutical
Timing of data capture Events occurs or at clinically-specified times Evaluated at prespecified time points
*Adapted from Bruner et al. (12). CTCAE, Common Terminology Criteria for Adverse Events.
TABLE 2 | Radiopharmaceutical patient-reported outcomes version of the CTCAE item formats*.
Please think back over the past 7 days: Example
Severity (51 symptomatic AE terms): what was the severity of your _______ at its worse? Abdominal pain (belly pain)
None/mild/moderate/severe/very severe
Frequency (25 symptomatic AE terms): how often did you have _______? Diarrhea (loose or watery stools)
Never/rarely/occasionally/frequently/almost constantly
Interference (25 symptomatic AE terms): how much did _______ interfere with your usual activities? Fatigue (lack of energy, tiredness)
Not at all/a little bit/somewhat/quite a bit/very much
Presence (21 symptomatic AE terms): did you have any _______? Bruising (black and blue marks)
No/yes
Amount (2 symptomatic AE terms): did you have any _______? Alopecia (hair loss)
Not at all/a little bit/somewhat/quite a bit/very much
*Adapted from Dueck et al. (14). AE, adverse events; CTCAE, Common Terminology Criteria for Adverse Events.
devices, or other therapies, digital therapeutics raise the
“quality” level of patient care for enhanced health outcomes
(18). At present, digital therapeutic devices are expected to
incorporate best health industry practices relating to design,
clinical testing, usability, and personal data security (18).
Regulatory bodies now recognize digital therapeutics as a
means to support drug product claims for risk, efficacy,
and intended clinical indication (18). Digital therapeutics
allow patients, healthcare providers, and payers to have
smart and handy tools to address health conditions through
high-quality, safe, and effective data-driven interventions
(18). One mechanism that the NCI might use to write-in
digital therapeutics in its trials is a centralized protocol
writing service.
PERSPECTIVES ON A CTEP CENTRALIZED
PROTOCOL WRITING SERVICE
NCI CTEP launched a Centralized Protocol Writing Service
(CPWS) to aid its Experimental Therapeutics Clinical Trials
Network (ETCTN) investigators for streamlined development
of clinical trial protocols (Figure 2). The CPWS offers this
service for the initial clinical trial document development
to support rapid protocol activation; it does not provide
service for post-activation protocol amendments. NCI CTEP
considers the principal investigator as the accountable leader
of a clinical team, meaning they are the individual who
interacts with the CPWS and who conducts the clinical
investigation. NCI CTEP presumes of the principal investigator
the role for protocol document oversight, the responsibility for
delegation of written tasks, and the provision of responses to
feedback from NCI CTEP, CPWS, or other regulatory agencies.
After a CPWS kick-off teleconference, there are iterative and
interactive feedback loops that are intended to incorporate
scientific, clinical, procedural, logistical, or regulatory items in
a clinical trial protocol document (Figure 2). Once reviewed
and approved by the principal investigator and the CPWS
team, NCI CTEP provides final review and obtains any need
additional reviews prior to actual protocol activation. As of
March 2019, two radiopharmaceutical clinical trial protocols
for radium-223 (Xofigo) were written by ETCTN principal
investigators and the CPWS. Protocol authoring by the CPWS
took an average 33 days, compared to a 60-day target.
The CPWS will be engaged in writing lutetium-177 dotatate
(Lutathera) radiopharmaceutical clinical trial protocols in the
near-term future.
CONCLUSION
NCI sponsored clinical trials have supported the growth and
execution of HRQOL and symptom management studies into
clinical trials through a variety of pilot opportunities as part
Frontiers in Oncology | www.frontiersin.org 4 October 2019 | Volume 9 | Article 1028
Kunos et al. Radiopharmaceutical Patient-Reported Outcomes
TABLE 3 | Reporting radiopharmaceutical trials with patient-reported outcomes.
Section Item CONSORT statement item Radiopharmaceutical PRO item
TITLE AND ABSTRACT
1a Identify of radiopharmaceutical in trial title Required for radiopharmaceutical trial
1b Structure a summary of design, methods, results, and conclusion Indicate if PRO is primary or secondary aim
INTRODUCTION
Background and objectives 2a Provide radiopharmaceutical background and rationale Provide rationale for PRO assessment
2b Specify hypotheses or clinical objectives State specific PRO hypothesis and objective
METHODS
Trial design 3a Describe trial phase and design Required for radiopharmaceutical trial
3b List methodological changes after trial commencement
Participants 4a List eligibility criteria for enrollees List any PRO-related eligibility criteria
4b List locations of where data were collected State PRO instrument, including how and
Interventions 5a List radiopharmaceutical interventions when they were assessed
5b List any non-radiopharmaceutical interventions Cite PRO instrument validity and reliability
Outcomes 6a Identify primary and any secondary outcome measures List any PRO primary or secondary aim
6b List intervention changes after trial commencement
Sample size 7a State how sample size was calculates Not required unless PRO is primary endpoint
7b Explain any interim analyses conducted or stopping rules executed
RANDOMIZATION
Sequence generation 8a Specify methodology for random allocation Option for radiopharmaceutical trial
8b Detail randomization type (such as blocking and block size) List any PRO-related stratification factors
Allocation concealment 9a Specify the mechanism for random allocation State approach, if any
9b Specify any steps taken to conceal allocation until assignment
Implementation 10a List who generated the random allocation State approach, if any
10b List who enrolled and assigned participants
Blinding 11a If done, state who was blinded to assigned interventions State approach, if any
11b Describe any similarities of interventions
Statistical methods 12a Describe statistical methods to compare interventions State approach for dealing with missing
12b List methods for any subgroup or adjusted analyses PRO data in analyses
RESULTS
Participant flow 13a List numbers of participants assigned, treated, and analyzed List numbers of participants at baseline
13b Identify numbers of participants excluded with reasons and other timepoints for PRO data
Recruitment 14a Define periods of trial recruitment and follow-up duration in the trial
14b List when the trial ended, including reason(s)
Baseline data 15a Provide table of baseline demographics and clinical data List any PRO-related eligibility criteria
15b List clinical indications for radiopharmaceutical administration
Numbers analyzed 16a List the number of participants (denominator) in analyses Detail each PRO domain and time point
16b Describe if the analysis was by original assigned groups Required for radiopharmaceutical trial
Outcomes estimation 17a State effect size and precision (like 95% confidence interval)
17b List absolute and relative effect for binary statistical outcomes
Ancillary analyses 18a Provide any subgroup ancillary analyses including PRO Required for radiopharmaceutical PRO
18b Distinguish between prespecified from exploratory analyses
Harms 19a Report any harms or unintended toxicity effects in each group Required for radiopharmaceutical PRO
19b Distinguish between prespecified from exploratory analyses
DISCUSSION
Limitations 20a Discuss limitations, addressing potential bias or imprecision Discuss radiopharmaceutical PRO-specific
20b Discuss any multiplicity of analyses limitations
Generalizability 21a Discuss generalizability of results considering prior evidence Discuss radiopharmaceutical PRO-specific
21b Discuss external validity and applicability of trial findings generalizability
Interpretation 22a Interpret findings, balancing benefits and harms of intervention Interpret radiopharmaceutical PRO in
22b Consider summary of other relevant evidence for context relation to clinical outcome and survival
(Continued)
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TABLE 3 | Continued
Section Item CONSORT statement item Radiopharmaceutical PRO item
OTHER INFORMATION
Registration and protocol 23 Provide number of trial registry, list if protocol can be accessed Required for radiopharmaceutical trial
Funding 24 Indicate source of funding or support, identify role of funders Required for radiopharmaceutical PRO
*Adapted from Calvert et al. (17). PRO, patient-reported outcome.
FIGURE 2 | NCI Cancer Therapy Evaluation Program (CTEP) centralized protocol writing service. Charted is the workflow for the U.S. National Cancer Institute’s
CTEP Centralized Protocol Writing Service (CPWS) Program. From left to right, the chart is organized by the main protocol authoring entity involved in document
writing inclusive of the Lead Protocol Organization, CTEP contract support (or CPWS), CTEP branches, or additional reviewers or other Federal agencies. Steps 1 and
2 initially activate CPWS protocol authoring. Steps 3 through 5 represent iterative and interactive feedback loops between CPWS and the principal investigator
charged with protocol authoring. Step 6 represents a joint principal investigator and CPWS approval of the draft protocol. Step 7 and Step 8 involve scientific and
logistical CTEP and non-CTEP reviews.
of protocol development. NCI investigators and stakeholders
appreciate that early phase clinical trials evaluate the safety,
and perhaps efficacy, of cancer treatment interventions among
a diverse spectrum of cancer disease stages. In some instances,
like the clinical development of radiopharmaceuticals, it makes
sense to incorporate HRQOL and/or PRO tools in the early
evaluation of agent safety when there is an anticipated impact
collectively on patients, their caregivers, and their family
members. This type of research can provide valuable data to
patients, investigators, and regulators in early phases of clinical
development before launching late phase clinical trials. The
new NCI CTEP CPWS provides early phase trial investigators
a means for iterative and interactive protocol writing, which
may include HRQOL or PRO assessments in NCI sponsored
clinical trials.
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